ZYMEWORKS ($ZYME) posted quarterly earnings results for Q4 2025 on Monday, March 2nd. The company reported earnings of -$0.55 per share, missing estimates of -$0.42 by $0.13. The company also reported revenue of $2,520,000, missing estimates of $13,847,856 by $-11,327,856.
You can see Quiver Quantitative's $ZYME stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ZYMEWORKS Insider Trading Activity
ZYMEWORKS insiders have traded $ZYME stock on the open market 10 times in the past 6 months. Of those trades, 0 have been purchases and 10 have been sales.
Here’s a breakdown of recent trading of $ZYME stock by insiders over the last 6 months:
- KENNETH GALBRAITH (Chair & CEO) has made 0 purchases and 4 sales selling 132,295 shares for an estimated $3,337,970.
- PAUL ANDREW MOORE (Chief Scientific Officer) has made 0 purchases and 3 sales selling 29,670 shares for an estimated $721,457.
- JEFFREY T L SMITH (EVP & Chief Medical Officer) has made 0 purchases and 2 sales selling 19,848 shares for an estimated $475,561.
- MARK HOLLYWOOD (EVP & Chief Operating Officer) sold 6,120 shares for an estimated $138,761
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ZYMEWORKS Hedge Fund Activity
We have seen 113 institutional investors add shares of ZYMEWORKS stock to their portfolio, and 98 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 6,521,591 shares (-95.3%) from their portfolio in Q4 2025, for an estimated $171,713,491
- REDMILE GROUP, LLC removed 3,214,096 shares (-86.7%) from their portfolio in Q4 2025, for an estimated $84,627,147
- BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. added 1,822,048 shares (+inf%) to their portfolio in Q4 2025, for an estimated $47,974,523
- SIREN, L.L.C. added 1,680,121 shares (+inf%) to their portfolio in Q4 2025, for an estimated $44,237,585
- BLACKSTONE INC. removed 1,616,290 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $42,556,915
- MORGAN STANLEY removed 1,391,505 shares (-34.9%) from their portfolio in Q4 2025, for an estimated $36,638,326
- PERCEPTIVE ADVISORS LLC added 1,171,187 shares (+56.0%) to their portfolio in Q4 2025, for an estimated $30,837,353
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ZYMEWORKS Analyst Ratings
Wall Street analysts have issued reports on $ZYME in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Truist Securities issued a "Buy" rating on 12/17/2025
- B. Riley Securities issued a "Buy" rating on 11/21/2025
- Stifel issued a "Buy" rating on 11/19/2025
- HC Wainwright & Co. issued a "Buy" rating on 11/18/2025
To track analyst ratings and price targets for ZYMEWORKS, check out Quiver Quantitative's $ZYME forecast page.
ZYMEWORKS Price Targets
Multiple analysts have issued price targets for $ZYME recently. We have seen 7 analysts offer price targets for $ZYME in the last 6 months, with a median target of $33.0.
Here are some recent targets:
- Asthika Goonewardene from Truist Securities set a target price of $40.0 on 12/17/2025
- Eva Fortea Verdejo from Wells Fargo set a target price of $33.0 on 12/12/2025
- Reni J. Benjamin from Citizens set a target price of $32.0 on 12/03/2025
- Mayank Mamtani from B. Riley Securities set a target price of $40.0 on 11/21/2025
- Stephen Willey from Stifel set a target price of $40.0 on 11/19/2025
- Robert Burns from HC Wainwright & Co. set a target price of $32.0 on 11/18/2025
- Brian Cheng from JP Morgan set a target price of $23.0 on 10/16/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
